Immune boosting cells show promise in fighting blood cancers after transplant

NCT ID NCT02727803

First seen Nov 06, 2025 · Last updated Apr 28, 2026 · Updated 18 times

Summary

This study tests whether giving patients personalized natural killer (NK) cells after chemotherapy and a cord blood transplant can help kill remaining cancer cells and reduce complications. It includes 100 adults with various blood cancers like leukemia, lymphoma, or multiple myeloma. The approach aims to improve long-term cancer control by using the patient's own immune cells to target the disease.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • M D Anderson Cancer Center

    RECRUITING

    Houston, Texas, 77030, United States

    Contact

Conditions

Explore the condition pages connected to this study.

ACCELERATED PHASE CHRONIC MYELOGENOUS LEUKEMIA, BCR-ABL1 POSITIVE ACUTE BIPHENOTYPIC LEUKEMIA ACUTE LYMPHOBLASTIC LEUKEMIA ACUTE LYMPHOBLASTIC LEUKEMIA IN REMISSION ACUTE MYELOID LEUKEMIA WITH MYELODYSPLASIA-RELATED CHANGES ACUTE MYELOID LEUKEMIA WITH VARIANT MLL TRANSLOCATIONS ACUTE MYELOID LEUKEMIA WITH VARIANT MLL TRANSLOCATIONS B ACUTE LYMPHOBLASTIC LEUKEMIA WITH T(9;22)(Q34.1;Q11.2); BCR-ABL1 B ACUTE LYMPHOBLASTIC LEUKEMIA WITH T(9;22)(Q34.1;Q11.2); BCR-ABL1 CHEMOTHERAPY-RELATED LEUKEMIA CHRONIC MYELOMONOCYTIC LEUKEMIA CHRONIC PHASE CHRONIC MYELOGENOUS LEUKEMIA, BCR-ABL1 POSITIVE HIGH GRADE B-CELL LYMPHOMA WITH MYC AND BCL2 OR BCL6 REARRANGEMENTS HIGH GRADE B-CELL LYMPHOMA WITH MYC AND BCL2 OR BCL6 REARRANGEMENTS ISS STAGE II PLASMA CELL MYELOMA ISS STAGE III PLASMA CELL MYELOMA ISS STAGE III PLASMA CELL MYELOMA MYELODYSPLASTIC SYNDROME MYELODYSPLASTIC SYNDROME WITH EXCESS BLASTS MYELODYSPLASTIC SYNDROME WITH EXCESS BLASTS MYELODYSPLASTIC SYNDROME WITH GENE MUTATION MYELODYSPLASTIC SYNDROME WITH GENE MUTATION MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASM MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASM PREVIOUSLY TREATED MYELODYSPLASTIC SYNDROME PREVIOUSLY TREATED MYELODYSPLASTIC SYNDROME RECURRENT ACUTE MYELOID LEUKEMIA RECURRENT ADULT ACUTE MYELOID LEUKEMIA RECURRENT HODGKIN LYMPHOMA RECURRENT NON-HODGKIN LYMPHOMA REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA REFRACTORY ADULT ACUTE LYMPHOBLASTIC LEUKEMIA SECONDARY ACUTE MYELOID LEUKEMIA SECONDARY ACUTE MYELOID LEUKEMIA THERAPY-RELATED MYELODYSPLASTIC SYNDROME THERAPY-RELATED MYELODYSPLASTIC SYNDROME